Development guidelines for MAbs serve as a blueprint for their manufacture, safety, and efficacy testing.
Gisela Cálas
Advertisement
Articles by Gisela Cálas
Advertisement
Latest Updated Articles
GMP Compliance for Production of CB.Hep-1 Monoclonal Antibody as a Biological ReagentPublished: February 1st 2006 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
Why Flexibility and Commercial Viability Must Be Built-in Early for Scaling CGTs
2
Analyzing the Safety and Scope of Next-Generation Gene Editing Platforms
3
How Rentschler Biopharma’s New Platforms Aim to Accelerate Biologics Development in Asia
4
Industry Leaders Detail Transformational Strategies to Mainstream CAR-T Care
5
